Related Experiment Video
Updated: Oct 5, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Progesterone reduces epithelial proliferation and attenuates prostatic hyperplasia in Spontaneously Hypertensive Rats
Giovanna Amaral Rodrigues1, Janaína Ribeiro Costa1, Bárbara Costa Malmann Medeiros1
1Department of Histology, Embryology, and Cell Biology, Federal University of Goiás, Av. Esperança, s/n, Campus Samambaia, Goiânia, Goiás, 74690-900, Brazil.
Abstract:
Considering little is known about the effects of progesterone (P4) on prostate biology, this study aimed to evaluate the influence of P4 on the ventral prostate of spontaneously hypertensive rats (SHR). 30-week-old male SHR were subjected to hormone or vehicle administration. P4 was administered at a dose of 70mg/kg/day (SHP and SHPT groups) and testosterone cypionate (T) at 1mg/kg/day (SHT and SHPT groups) for 4 weeks. Control groups (SHC, SHCT, and SHCC) received the corresponding volume of the vehicle following the same protocol. At the end of treatment (8.5 months of age), ventral prostates were collected and subjected to biometrical, morphological, morphometrical, stereological, biochemical, ultrastructural, histopathological, serological, and immunohistochemical analyses. P4 promoted a reduction in both total and relative weights of all prostatic lobes, even when administered in combination with T. However, only SHP animals showed a reduced relative frequency of alveoli exhibiting intense hyperplasia. In addition, a marked reduction in epithelial cell proliferation was observed in animals treated with P4 alone or associated with T. Collectively, these findings demonstrate that P4 induces a pronounced reduction in prostate size, attenuates prostatic hyperplasia in SHR, and exerts a potent antiproliferative effect on epithelial cells of the ventral prostate. These effects may result from tissue atrophy induced by the systemic effects of P4. However, a direct action of P4, mediated through genomic and/or non-genomic mechanisms, either independently or in combination with its systemic effects, cannot be ruled out.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Vasodilators
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Action of β1 Blockers
Hormonal Regulation